Organigram Global Inc. (OGI) SEC filings

OGINasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 16, 2025Score 4/30

$0.83−0.01 (-0.65%)

Close on Nov 13, 2026Market cap $111.41MP/E –Yield –

SEC filings

40 of Organigram Global's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 12, 2026	Nov 13, 2026	SEC EDGAR
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Nov 3, 2026	Nov 3, 2026	SEC EDGAR
Current report	6-K	Oct 15, 2026	Oct 15, 2026	SEC EDGAR
Current report	6-K	Sep 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	6-K	Sep 30, 2026	Sep 3, 2026	SEC EDGAR
Current report	6-K	Feb 18, 2026	Sep 1, 2026	SEC EDGAR
Current report	6-K	Aug 20, 2026	Aug 20, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Aug 11, 2026	SEC EDGAR
Current report	6-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	6-K	Jul 20, 2026	Jul 20, 2026	SEC EDGAR
Current report	6-K	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	6-K	May 6, 2026	May 6, 2026	SEC EDGAR
Current report	6-K	Apr 15, 2026	Apr 16, 2026	SEC EDGAR
Current report	6-K	Mar 30, 2026	Mar 31, 2026	SEC EDGAR
Current report	6-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Current report	6-K	Mar 10, 2026	Mar 11, 2026	SEC EDGAR
Current report	6-K	Feb 23, 2026	Mar 9, 2026	SEC EDGAR
Current report	6-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	6-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	6-K	Feb 24, 2026	Feb 24, 2026	SEC EDGAR
Current report	6-K	Feb 20, 2026	Feb 20, 2026	SEC EDGAR
Current report	6-K	Feb 19, 2026	Feb 20, 2026	SEC EDGAR
Current report	6-K	Feb 19, 2026	Feb 19, 2026	SEC EDGAR
Current report	6-K	Feb 18, 2026	Feb 18, 2026	SEC EDGAR
Current report	6-K	Dec 31, 2025	Feb 10, 2026	SEC EDGAR
Current report	6-K	Feb 3, 2026	Feb 3, 2026	SEC EDGAR
Current report	6-K	Jan 27, 2026	Jan 28, 2026	SEC EDGAR
Current report	6-K	Dec 31, 2025	Dec 31, 2025	SEC EDGAR
Annual report	40-F	Sep 30, 2025	Dec 16, 2025	SEC EDGAR
Current report	6-K	Dec 5, 2025	Dec 5, 2025	SEC EDGAR
Current report	6-K	Dec 4, 2025	Dec 4, 2025	SEC EDGAR
Current report	6-K	Nov 25, 2025	Nov 25, 2025	SEC EDGAR
Current report	6-K	Oct 29, 2025	Oct 29, 2025	SEC EDGAR
Current report	6-K	Oct 21, 2025	Oct 21, 2025	SEC EDGAR
Current report	6-K	Oct 9, 2025	Oct 9, 2025	SEC EDGAR
Current report	6-K	Sep 2, 2025	Sep 2, 2025	SEC EDGAR
Current report	6-K	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	6-K	Aug 1, 2025	Aug 1, 2025	SEC EDGAR
Current report	6-K	Jul 8, 2025	Jul 8, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Organigram Global's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Dec 19, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OGI.

Compare: OGI vs INCR · OGI vs CGC · OGI vs ACB · OGI vs VREOF · OGI vs LGND

Revenue growth77.8% · median 10.7%

Gross margin34.8% · median 35.9%

Operating margin-5.9% · median 1.3%

Company	Revenue	Growth
VREOF	$673.67M	+255.8%
CGC	C$308.32M	+10.7%
OGI	C$259.18M	+77.8%
LGND	$253.83M	+1.0%
INCR	–	–
ACB	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: September 30
Held by institutions: 5.7%
Auditor: PKF OConnor Davies, LLP
SEC CIK: 1620737

Advertisement
300 × 250

See a number that looks wrong?